2025 China Antibodies Market Revenue Opportunities Report
Description
The 2025 China Antibodies Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibody market in China include WuXi Biologics, Asymchem, Hansoh Pharmaceuticals, and Shanghai Pharma Industrial. WuXi Biologics is a global leader offering end-to-end biologics solutions with over 30,000 liters of manufacturing capacity and expertise in antibody-drug conjugates (ADCs) and next-generation cell lines, serving clients worldwide. Asymchem is recognized for innovative antibody engineering and sustainable manufacturing practices. Hansoh Pharmaceuticals focuses on therapeutic antibodies and biosimilars, optimizing cost without sacrificing quality. Shanghai Pharma Industrial provides custom antibody development and has strong large-scale production capabilities mainly across Asia-Pacific.
China’s antibody market is rapidly growing, accounting for about 10% of the global market share, with a forecasted revenue increase to USD 1,656.7 million by 2030 and a CAGR of 16.6%. This growth is fueled by domestic companies’ focus on biosimilars and contract manufacturing, alongside emerging innovative biologics like CAR-T and CRISPR-based therapies. Chinese companies contribute significantly to innovative pipelines, especially in antibody-drug conjugates and bispecific antibodies, representing over 50% of the clinical pipeline globally in these niches. Thus, these companies are pivotal to China’s expanding presence in the global antibody market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibody market in China include WuXi Biologics, Asymchem, Hansoh Pharmaceuticals, and Shanghai Pharma Industrial. WuXi Biologics is a global leader offering end-to-end biologics solutions with over 30,000 liters of manufacturing capacity and expertise in antibody-drug conjugates (ADCs) and next-generation cell lines, serving clients worldwide. Asymchem is recognized for innovative antibody engineering and sustainable manufacturing practices. Hansoh Pharmaceuticals focuses on therapeutic antibodies and biosimilars, optimizing cost without sacrificing quality. Shanghai Pharma Industrial provides custom antibody development and has strong large-scale production capabilities mainly across Asia-Pacific.
China’s antibody market is rapidly growing, accounting for about 10% of the global market share, with a forecasted revenue increase to USD 1,656.7 million by 2030 and a CAGR of 16.6%. This growth is fueled by domestic companies’ focus on biosimilars and contract manufacturing, alongside emerging innovative biologics like CAR-T and CRISPR-based therapies. Chinese companies contribute significantly to innovative pipelines, especially in antibody-drug conjugates and bispecific antibodies, representing over 50% of the clinical pipeline globally in these niches. Thus, these companies are pivotal to China’s expanding presence in the global antibody market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
